References
- Fala L. Trulicity (Dulaglutide): a new GLP-1 receptor agonist once-weekly subcutaneous injection approved for the Treatment of patients with type 2 diabetes. Am Health Drug Benefits. 2015;8(Spec Feature):131-134.
- Smith LL, Mosley JF 2nd, Parke C, et al. Dulaglutide (Trulicity): the third once-weekly GLP-1 agonist. P T. P & T: a peer-reviewed Journal for Formulary Management. 2016;41(6):357–360.
- Ryan D, Acosta A. GLP-1 receptor agonists: nonglycemic clinical effects in weight loss and beyond. Obesity (Silver Spring). 2015;23(6):1119–1129.
- Lilly E. TRULICITY (dulaglutide) U.S. Prescribing Information. [ Cited Oct 2022]. Available from:https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125469s046s052lbl.pdf.
- Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121–130.
- Lilly E. TRULICITY (dulaglutide) CHN Prescribing Information. [ Cited Oct 2022]. Available from: https://db.yaozh.com/jinkou?jinkouchanpinmingchengzhongwen%7Cjinkouchanpinmingchengyingwen=%E5%BA%A6%E6%8B%89%E7%B3%96%E8%82%BD%E6%B3%A8%E5%B0%84%E6%B6%B2&jinkoushangpinmingzhongwen%7Cjinkoushangpinmingyingwen=&jinkougongsimingchengzhongwen%7Cjinkougongsimingchengyingwen=&jinkouguigezhongwen=&jinkoujixingzhongwen=&jinkouzhucezhenghao=&jinkoufazhengriqistr=&jinkoufazhengriqiend.
- Kadam V, Bagde S, Karpe M, et al. A Comprehensive Overview on Biosimilars. Curr Protein Pept Sci. 2016;17(8):756–761.
- Shyamala KY, Comprehensive A. Review of biosimilars. World J Pharm Res. 2019;8(13)851–867.
- US Food and Drug Administration (2015). Scientific considerations in demonstrating biosimilarity to a reference product. Guidance for industry. [Cited Oct 2022]. Available from: https://www.fda.gov/media/82647/download.
- European Medicines Agency (2014). Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. [Cited Oct 2022]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-similar-biological-medicinal-products-containing-biotechnology-derived-proteins-activeen-0.pdf.
- China National Medical Products Administration (2015).Technical guidelines for research and evaluation of biosimilars. [Cited Oct 2022]. Available from: https://www.cde.org.cn/zdyz/domesticinfopage?zdyzIdCODE=f044cdf4b7d7286aa12ffb85fc81a74c.
- World Health Organization (2022). Guidelines on evaluation of biosimilars. [Cited Oct 2022]. Available from:https://www.who.int/publications/m/item/guidelines-on-evaluation-of-biosimilars.
- China National Medical Products Administration (2020). Guidance for designing clinical trials of biosimilars of liraglutide injection. [Cited Oct 2022]. Available from: https://www.nmpa.gov.cn/directory/web/nmpa/images/uL28iAxICAgobbA+8CtwrPrxNeiyeTSusn6zuA4MvG0break/qnB2bSyytTR6cnovMbWuLW81K3U8qG3LnBkZg==.pdf.
- Morieri ML, Frison V, Rigato M, et al. Effectiveness of dulaglutide in the real world and in special populations of type 2 diabetic patients. J Clin Endocrinol Metab. 2020;105(7):dgaa204.
- Xu J, Zhang Y, Li Y, et al. Pharmacokinetics, pharmacodynamics, and safety of dulaglutide after single or multiple doses in Chinese healthy subjects and patients with T2DM: a randomized, placebo-controlled, phase I study. Adv Ther. 2022;39(1):488–503.